Highlight
Summary
About the Role
About You
- Ph.D. or Pharm.D. in pharmacometrics, clinical pharmacology, pharmacokinetics, or a related field.
- 10+ years of experience in the pharmaceutical or biotechnology industry.
- Demonstrated leadership in pharmacometric strategy and successful regulatory interactions.
- Expert knowledge of population PK/PD modeling, simulation, and quantitative pharmacology principles.
- Hands-on experience with software tools such as NONMEM, Monolix, R, Phoenix NLME, and other modeling platforms.
- Experience in building or leading pharmacometric functions in a biotech or pharma setting.
- Excellent scientific communication, leadership, and organizational skills.
- Ability to operate effectively in a dynamic, entrepreneurial, and resource-limited environment.
Benefits
- Comprehensive medical and dental insurance.
- Vision, life and disability insurance.
- Health savings account and flexible savings.
- Dependent care benefits.
- 401(k) plan.
- Highly attractive stock options.
At Nura Bio (previously known as Proneurotech Inc.), we envision a world where the diagnosis of a neurological disorder comes with the hope of a cure. Expanding on recent breakthroughs in crucial neurodegenerative pathways, we are positioned to deliver transformative neuroprotective therapies to prevent and protect against neuronal loss and related neuroimmune dysregulation. Our research and development strategy is currently centered on two approaches: prevention of neuronal loss to preserve neurological function; and restoring the function of the neuron-glia axis to improve the nervous system’s immune surveillance capacity in response to neurological injury. Our discovery engine and emerging multi-target pipeline spans these approaches and is well positioned to address a broad range of neurological diseases. Nura Bio’s lead program is the SARM1 inhibitor program. SARM1, has recently emerged an axon-intrinsic metabolic sensor that is a pivotal driver of axonal degeneration and neuronal integrity. Axon degeneration is an early event in several neurological disorders, and halting it early has tremendous potential in the treatment of central, peripheral, and ocular neurological diseases.